Search Results - "Brosens, L A A"

Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy by Defize, I. L., van der Horst, S., Bülbul, M., Haj Mohammad, N., Mook, S., Meijer, G. J., Brosens, L. A. A., Ruurda, J. P., van Hillegersberg, R.

“…Background Patients  with esophageal cancer  that invades adjacent structures (cT4b) are precluded from surgery and usually treated with definitive…”
Get full text

A novel likely pathogenetic variant p.(Cys235Arg) of the MEN1 gene in multiple endocrine neoplasia type 1 with multifocal glucagonomas by Smirne, C., Giacomini, G. M., Berton, A. M., Pasini, B., Mercalli, F., Prodam, F., Caputo, M., Brosens, L. A. A., Mollero, E. L. M., Pitino, R., Pirisi, M., Aimaretti, G., Ghigo, E.

“…Purpose Multiple endocrine neoplasia type 1 (MEN1) is a hereditary endocrine syndrome caused by pathogenic variants in MEN1 tumor suppressor gene. Diagnosis is…”
Get full text

Diagnostic accuracy of contrast-enhanced diffusion-weighted MRI for liver metastases of pancreatic cancer: towards adequate staging and follow-up of pancreatic cancer - DIA-PANC study: study protocol for an international, multicenter, diagnostic trial by Litjens, G, Rivière, D M, van Geenen, E J M, Radema, S A, Brosens, L A A, Prokop, M, van Laarhoven, C J H M, Hermans, J J

“…At the time of surgery, approximately 10-20% of the patients with pancreatic cancer are considered unresectable because of unexpected liver metastasis,…”
Get full text

Single-Step Treatment with Limited Endoscopic Resection and Cryoballoon Ablation Is Feasible and Safe in an Esophageal Porcine Model by Overwater, A., Brosens, L. A. A., Offerhaus, G. J. A., Weusten, B. L. A. M.

“…Background Treatment of Barrett’s neoplasia consists of two steps: endoscopic resection of visible lesions with subsequent ablation of remaining Barrett’s…”
Get full text

DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment by Conemans, E B, Lodewijk, L, Moelans, C B, Offerhaus, G J A, Pieterman, C R C, Morsink, F H, Dekkers, O M, de Herder, W W, Hermus, A R, van der Horst-Schrivers, A N, Drent, M L, Bisschop, P H, Havekes, B, Brosens, L A A, Dreijerink, K M A, Borel Rinkes, I H M, Timmers, H Th M, Valk, G D, Vriens, M R

“…Objective Epigenetic changes contribute to pancreatic neuroendocrine tumor (PanNET) development. Hypermethylation of promoter DNA as a cause of tumor…”
Get full text

Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis by van Hattem, W A, Brosens, L A A, de Leng, W W J, Morsink, F H, Lens, S, Carvalho, R, Giardiello, F M, Offerhaus, G J A

“…Juvenile polyposis syndrome (JPS) is a rare autosomal dominant disorder characterised by multiple gastrointestinal juvenile polyps and an increased risk of…”
Get more information

The ISCON-trial protocol: laparoscopic ischemic conditioning prior to esophagectomy in patients with esophageal cancer and arterial calcifications by Veen, A van der, Schiffmann, L M, de Groot, E M, Bartella, I, de Jong, P A, Borggreve, A S, Brosens, L A A, Santos, D Pinto Dos, Fuchs, H, Ruurda, J P, Bruns, C J, van Hillegersberg, R, Schröder, W

“…Anastomotic leakage is the most important surgical complication following esophagectomy. A major cause of leakage is ischemia of the gastric tube that is used…”
Get full text

Mucosal prolapse syndrome presenting as rectal polyposis by Brosens, L A A, Montgomery, E A, Bhagavan, B S, Offerhaus, G J A, Giardiello, F M

“…Mucosal prolapse syndrome comprises a variety of clinical and histopathological entities, with mucosal prolapse as the underlying pathogenic mechanism. Due to…”
Get more information

Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer by Tol, J. A. M. G., Brosens, L. A. A., van Dieren, S., van Gulik, T. M., Busch, O. R. C., Besselink, M. G. H., Gouma, D. J.

“…Background According to some studies, the number of lymph nodes with metastases in relation to the total number of removed lymph nodes, the lymph node ratio…”
Get full text

Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review by van Roessel, S, Janssen, B V, Soer, E C, Fariña Sarasqueta, A, Verbeke, C S, Luchini, C, Brosens, L A A, Verheij, J, Besselink, M G

“…Abstract Background Preoperative chemo(radio)therapy is used increasingly in pancreatic cancer. Histological evaluation of the tumour response provides…”
Get full text

Refraining from resection in patients with potentially curable gastric carcinoma by Gertsen, Emma C., Brenkman, Hylke J.F., Brosens, L.A.A., Luijten, Josianne C.H.B.M., Mohammad, Nadia Haj, Verhoeven, Rob H.A., van Hillegersberg, Richard, Ruurda, Jelle P.

“…Surgical resection is the cornerstone of curative treatment for gastric cancer. The aim of this study was to evaluate reasons for and patient- and tumor…”
Get full text

Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study by van der Veen, A., Seesing, M.F.J., Wijnhoven, B.P.L., de Steur, W.O., van Berge Henegouwen, M.I., Rosman, C., van Sandick, J.W., Mook, S., Haj Mohammad, N., Ruurda, J.P., Brosens, L.A.A., van Hillegersberg, R., Alderlieste, Y.A., Baas, P.C., Belt, E.J.T., Ünlü, C., de Waard, J.W.D., Duijvendijk, P., Heisterkamp, J., Kouwenhoven, E.A., Nieuwenhuijzen, G.A.P., Pierik, E.G.J.M., Plukker, J.T.M., Pronk, A., Rijken, A.M., Scheepers, J.J.G., Stoot, J.H., Tetteroo, G.W.M., van Acker, G.J.D., van der Harst, E., van der Peet, D.L.

“…The aim of this study is to provide insight in accuracy of diagnosing, current treatment and survival in patients with resectable esophageal and gastric…”
Get full text

Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement by van der Wel, M J, Klaver, E, Pouw, R E, Brosens, L A A, Biermann, K, Doukas, M, Huysentruyt, C, Karrenbeld, A, ten Kate, F J W, Kats-Ugurlu, G, van der Laan, J, van Lijnschoten, I, Moll, F C P, Offerhaus, G J A, Ooms, A H A G, Seldenrijk, C A, Visser, M, Tijssen, J G, Meijer, S L, Bergman, J J G H M

“…Abstract Endoscopic resection (ER) is an important diagnostic step in management of patients with early Barrett’s esophagus (BE) neoplasia. Based on ER…”
Get full text

Microscopic resection margin status in pancreatic ductal adenocarcinoma – A nationwide analysis by Daamen, L.A., van Goor, I.W.J.M., Schouten, T.J., Dorland, G., van Roessel, S.R., Besselink, M.G., Bonsing, B.A., Bosscha, K., Brosens, L.A.A., Busch, O.R., van Dam, R.M., Fariña Sarasqueta, A., Festen, S., Groot Koerkamp, B., van der Harst, E., de Hingh, I.H.J.T., Intven, M.P.W., Kazemier, G., de Meijer, V.E., Nieuwenhuijs, V.B., Raicu, G.M., Roos, D., Schreinemakers, J.M.J., Stommel, M.W.J., van Velthuysen, M.F., Verheij, J., Verkooijen, H.M., van Santvoort, H.C., Molenaar, I.Q.

“…First, this study aimed to assess the prognostic value of different definitions for resection margin status on disease-free survival (DFS) and overall survival…”
Get full text

Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI by van Kessel, C S, de Boer, E, ten Kate, F J W, Brosens, L A A, Veldhuis, W B, van Leeuwen, M S

“…To assess the range of hepatobiliary enhancement patterns of focal nodular hyperplasia (FNH) after gadoxetic-acid injection, and to correlate these patterns to…”
Get more information

ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field by Schurink, B., Seesing, M.F.J., Goense, L., Mook, S., Brosens, L.A.A., Mohammad, N. Haj, Ruurda, J.P., Roeling, T.A.P., Bleys, R.L.A.W., van Hillegersberg, R.

“…A subset of oesophageal cancer patients has residual nodal disease despite complete pathologic response of the primary tumour after neoadjuvant chemoradiation…”
Get full text

Prevention and management of duodenal polyps in familial adenomatous polyposis by Brosens, L A A, Keller, J J, Offerhaus, G J A, Goggins, M, Giardiello, F M

“…[...]duodenal adenomas seem less responsive to chemoprevention with NSAIDs than colonic counterparts. Summary [black right triangle] FAP is characterised by…”
Get full text

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial by van Dam, J L, Verkolf, E M M, Dekker, E N, Bonsing, B A, Bratlie, S O, Brosens, L A A, Busch, O R, van Driel, L M J W, van Eijck, C H J, Feshtali, S, Ghorbani, P, de Groot, D J A, de Groot, J W B, Haberkorn, B C M, de Hingh, I H, van der Holt, B, Karsten, T M, van der Kolk, M B, Labori, K J, Liem, M S L, Loosveld, O J L, Molenaar, I Q, Polée, M B, van Santvoort, H C, de Vos-Geelen, J, Wumkes, M L, van Tienhoven, G, Homs, M Y V, Besselink, M G, Wilmink, J W, Groot Koerkamp, B

“…Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for…”
Get full text

Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study by Borggreve, A S, Mook, S, Verheij, M, Mul, V E M, Bergman, J J, Bartels-Rutten, A, Ter Beek, L C, Beets-Tan, R G H, Bennink, R J, van Berge Henegouwen, M I, Brosens, L A A, Defize, I L, van Dieren, J M, Dijkstra, H, van Hillegersberg, R, Hulshof, M C, van Laarhoven, H W M, Lam, M G E H, van Lier, A L H M W, Muijs, C T, Nagengast, W B, Nederveen, A J, Noordzij, W, Plukker, J T M, van Rossum, P S N, Ruurda, J P, van Sandick, J W, Weusten, B L A M, Voncken, F E M, Yakar, D, Meijer, G J

“…Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR)…”
Get full text

Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival by Visser, E., Franken, I. A., Brosens, L. A. A., de Leng, W. W. J., Strengman, E., Offerhaus, J. A., Ruurda, J. P., van Hillegersberg, R.

“…Summary Survival of patients with esophageal adenocarcinoma remains poor and individual differences in prognosis remain unexplained. This study investigated…”
Get full text